ASCO 2023

Sonia trial: How does the new data change clinical…

ADC revolution: How can the new results be integrated…

CDK4/6i in EBC: Have abema and ribo arrived in the…

PART1: How to de-escalate chemotherapy? What is the…

PART2: Trying to understand optimal therapy for…

Expanding CDK4/6i therapy in EBC: How to select…

Chemotherapy de-escalation in HER2+ patients:…

New data on Ribocilib in adjuvant setting EBC: What…

First data with adjuvant ribociclib

Chemo-immunotherapeutic signals especially in HER2low…

Early follow-up shows clear benefit

1/3 of patients with HER2+ in future without…

10 years update on ShortHER

Checkpoint inhibition in endometrial cancer: new…

Discussions on CDK4/6 inhibitors in EBC

PHERGain opens the possibility to avoid chemotherapy in…

Young patients benefit from ovarian suppression

A challenge for clinical management

TILs in HER2+ disease - prognostic, but not enough to…

TILs are prognostic but not predictive in HER2+ EBC

Tumor-informed ctDNA likely prognostic for relapse in…

More CDK4/6 options for EBC patients

De-escalation of CT for early BC

My EBC highlights from ASCO23

Can we preserve our patients form chemotherapy?

From PENELOPE-B to SURVIVE

Ovarian function - Ovarian suppression not necessary in…

White blood cells with increasing prognostic relevance?…

Ribociclib improves iDFS

Palbociclib after Palbociclib might not be the best…

Ribociclib has arrived in the adjuvant setting

Another proof of efficacy of immunotherapy in advanced…

SOC of ovarian ablation confirmed in meta-analysis.

Practice changing or not quite yet?

Analyses of ctDNA in PENELOPE-B: Test methods are…

TILs subtypes are associated with clinical features and…

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

Eine Herausforderung für das klinische Management

Kolejny dowód na skuteczność immunoterapii w…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

Primele date cu ribociclib adjuvant

Tumor-informed ctDNA wahrscheinlich prognostisch für…

Czy wystarczy, aby zmienić standardy?

1/3 der Patientinnen mit HER2+ zukünftig ohne…

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

Palbociclib después de Palbociclib podría no ser la…

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

I miei punti salienti di ASCO23

NATALEE nicht überraschend aber überzeugend positiv

TILs w rakach HER2+ - znaczenie rokownicze, ale nie…

Response adaptierte, Chemotherapie-freie Option beim…

Von PENELOPE-B zur SURVIVE

Eine Herausforderung für viele Patienten, wenig…

PHERGain abre la posibilidad de evitar la quimioterapia…

What is the optimal therapie sequence for HR+ MBC…

E-Health Applications in Oral Cancer Therapy

The start of precision medicine in HR+ breast cancer

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo…

Mises à jour sur les ADC dans le cancer du sein…

Update ADC efficacy

CDK4/6 Sequencing? ESR-1 not ready for prime time?…

CDK4/6i in first line and beyond & Biomarkers

Reassuring real-world data!

ARASEC: ADT + Daralutamide for mHSPC

DEAR trial: real-world comparator analyses of ARIs

PRL-02: Intramuscular arbiraterone

Confirming results for PARPi in mCRPC

AI for prediction in local prostate carcinoma

PAPR-inhibitors: Patient-selection matters!

Metastasis-directed for prostate cancer

TALAPRO-2: Results and controversies

Part2: Important update on testosterone-recovery

Over-staging of bone scan compared with PSMA PET/CT

PSA nadir 6 month after Radiotherapy is strong…

LuPARP combination study: LuPSMA and Olaparib in mCRPC

PEACE 1 - results and controversies

Part 1: Important update on testosterone-recovery

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Intensifierad eller de-intensifierad behandling vid…

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PARP-inhibitors: La selección de pacientes es…

Triple therapy in mCSPC - which is the ideal partner…

PARPi in PCa: more genetic testing is required as PRO…

Best of Bladder: ddMVC increases DFS! Standard…

Q-TWiST in the therapy of aUC

FGFR inhibition

New standard for MIBC

Extent of lymphadenectomy in cystectomy

Enfortumab vedotin + pembrolizumab 1stL in…

First line in cisplatin-ineligible advance urothelial…

Targeted therapies in advanced urothelial cancer: The…

New SoC option for metastatic bladder cancer

Nouvelles options de soins standard pour le cancer de…

Best of Bladder: ddMVC increases DFS! Standard…

Primera línea en cáncer urotelial avanzado no elegible…

The efficacy of neo-adjuvant therapy (ddMVAC,…

Update EV/Pembro, Avelumab Maintenance

Long term follow up in advanced renal cell cancer: Is…

Non ccRCC: how should we treat patients today?

Primary endpoint not reached: what do we learn from…

1st Line therapy RCC: which combination to choose?

New data non ccRCC

News from the adjuvant

IO rechallenge in mRCC

Lenvatinib + pembrolizumab in non-clear cell renal cell…

New standard for 2nd line RCC?

Update and take home message of 1st Line mRCC

The value of perioperative chemo-IO in rNSCLC and the…

ADAURA - results and controversies

An imperfect analysis, but perfect results

Which should we prefer: neoadjuvant, adjuvant or…

Perioperative treatment

EGFR testing necessary in the adjuvant setting

Added benefit of perioperative chemo/IO in stage 2-3b…

Adjuvant IO in KRASm patients

Another neoadjuvant chemo/IO option

Adjuvant and neoadjuvant strategies in resectable NSCLC

Role of periopertative IO confirmed

A new standard of care for operated patients with…

Confirmation of neoadjuvant immunotherapy

More options in the perioperative setting

ADAURA - Discussion closed?

A new standard of care

A chemo-free preop. IO strategy?

CheckMate 9LA: 4‑year clinical update

OS benefit from EGFR receptor TKI

Toegevoegde waarde van periperatief chemo-immuno bij…

ADAURA- discussie gesloten?

Que devrions-nous préférer: traitement néoadjuvant,…

Más opciones en el entorno perioperatorio

Un nouveau standard therapeutique pour les patients…

Stratégies adjuvantes et néoadjuvantes dans le CBNPC…

TTF-treatment requires further studies

Sotorasib: clear clinical benefit, but short follow-up…

Does ADC + chemo + IO replace the existing concepts?

Update on KRASG12Cm treatment options - how to proceed?

Zorifertinib: an option when osimertinib is not…

LUNAR: TTF medical device shows OS-benefit, but more…

TROP2-ADC shows high response rates in 1L-combination…

ADC + ICI ± Pt-CT in patients with aNSCLC

IO in EGRF positive patients post TKI

CORRELATE - a real world analysis

New data from another BiTE

More BiTEs, more possibilities

Can we incoporate biomarkers in SCLC treatment?

Treatment strategies in SCLC

Hyperfractionated radiotherapy for SCLC

Más BiTEs, más posibilidades

Kunnen we biomarkers gebruiken om behandeling te…

ONCOalert (inclusive patient advocates) consensus on…

Immune checkpoint inhibitors in malignant mesothelioma